Clinical Trial Search

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…

Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162

Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 23; 21; 23; 21 Participants

Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Change in Best Corrected Visual Acuity — 6.0; 4.6 Change in letters (BCVA)

Primary: Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF) — 58.7; 4.5 letters…

Primary: Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — 0.1; 1.0 Letters correctly read

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. — 2.5; 4.6 ETDRS Letters — p=0.0083

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants

Primary: Vision — 0.16 logMAR

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Mean Change From Baseline in BCVA at Week 8 — 6.4; 6.5 Letters

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236

Primary: Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4 — 360.9; -62.0 Microns

Primary: Macular Edema — 416 Microns